An observational study in Multiple Sclerosis, sponsored by Bayer. Completed. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2018-06-21.
Sponsored by Bayer · Observational
Among 37 studies in Multiple Sclerosis by Bayer — none open to participants now, 1 under way, none of them phase 3. Multiple Sclerosis · Bayer.
Among the 37 studies in Multiple Sclerosis by Bayer, this one is the 16th largest by enrollment of the 28 observational ones that give a count, is one of 4 that started in 2009, is one of 28 observational ones, and was the 33rd registered.
3,267 studies on the registry are indexed under Multiple Sclerosis; 662 are open to participants now.
Browse Multiple Sclerosis studies →None of the 37 studies in Multiple Sclerosis by Bayer is open now. The open studies under Multiple Sclerosis, anywhere →
Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 100 across 971 observational studies indexed under Multiple Sclerosis.
Median enrollment 71 across the 9 interventional studies, 145 across the 28 observational. Of the 34 that completed or were terminated, 3 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 37 studies in Multiple Sclerosis by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the adherence to the treatment with interferon beta-1b, in patients diagnosed with isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), or secondary progressive multiple sclerosis (SPMS) who had more than 6 months in treatment.
This study included patients who had been on interferon beta-1b for more than 6 months and who agreed to participate in this study.
Exclusion Criteria:
-
Patients with CIS, RRMS or SPMS who had more than 6 months in treatment
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Interferon beta-1b (INFb-1b) was used at the standard dose of 250 mg/ml.
Self-reported adherence to INFb-1b in the previous four weeks assessed by Morisky-Green (MG) test
Time frame: Four weeks just before baseline visit
Demographic data
Age, sex, marital status, education level, employment status
Time frame: At baseline
Number of patients with MS diagnosis
Time frame: At baseline
Age at first episode and at diagnosis
Time frame: At baseline
Time since last relapse
Time frame: At baseline
Assessment of general health status using data from a questionnaire or from their clinical history collected by the investigator team
Time frame: At baseline
Expanded Disability Status Scale (EDSS) to assess the degree of disability caused by MS
The EDSS quantifies the disability in eight functional systems (FS) and allows neurologists to assign a level of Functional System in each of them caused by multiple sclerosis.
Time frame: At baseline
Number of patients with adverse events during the last month
Time frame: Four weeks just before baseline visit
Clinical setting characteristics like existence of MS unit
The existence of Multiple Sclerosis Unit was evaluated bearing in mind if the hospital had or had not available a Multiple Sclerosis Unit into the hospital Neurology Department.
Time frame: At baseline
Time on INFb-1b therapy
Time frame: At baseline
No study locations are listed for this record.
Ran from Feb 2009 to primary completion in Mar 2010, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.